NO20083716L - Prosess for tilberedning av vannloselige polyetylenglykol konjugater av immunosuppressive makrolider. - Google Patents

Prosess for tilberedning av vannloselige polyetylenglykol konjugater av immunosuppressive makrolider.

Info

Publication number
NO20083716L
NO20083716L NO20083716A NO20083716A NO20083716L NO 20083716 L NO20083716 L NO 20083716L NO 20083716 A NO20083716 A NO 20083716A NO 20083716 A NO20083716 A NO 20083716A NO 20083716 L NO20083716 L NO 20083716L
Authority
NO
Norway
Prior art keywords
preparation
water
polyethylene glycol
soluble polyethylene
glycol conjugates
Prior art date
Application number
NO20083716A
Other languages
English (en)
Inventor
Mark Edward Ruppen
Jianxin Gu
Tianmin Zhu
Mahdi B Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20083716L publication Critical patent/NO20083716L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives fremgangsmåter for fremstilling av 42-pegylerte rapamyciner, omfattende omsetning av et rapamycin med et acyleringsmiddel i nærvær av en lipase, hvilket gir et acylert rapamycin, og omsetning av det acylerte rapamycin med et metoksy-poly(etylenglykol)derivat i nærvær av en base. Det beskrives også fremgangsmåter for fremstilling av 32-pegylert tacrolimus og/eller ascomycin ved anvendelse av disse trinn.
NO20083716A 2006-03-07 2008-08-29 Prosess for tilberedning av vannloselige polyetylenglykol konjugater av immunosuppressive makrolider. NO20083716L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77993906P 2006-03-07 2006-03-07
PCT/US2007/005646 WO2007103348A2 (en) 2006-03-07 2007-03-05 Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants

Publications (1)

Publication Number Publication Date
NO20083716L true NO20083716L (no) 2008-10-06

Family

ID=38420553

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083716A NO20083716L (no) 2006-03-07 2008-08-29 Prosess for tilberedning av vannloselige polyetylenglykol konjugater av immunosuppressive makrolider.

Country Status (19)

Country Link
US (1) US7605257B2 (no)
EP (1) EP1993610A2 (no)
JP (1) JP2009529050A (no)
KR (1) KR20080106225A (no)
CN (1) CN101394867A (no)
AR (1) AR059740A1 (no)
AU (1) AU2007223963A1 (no)
BR (1) BRPI0708562A2 (no)
CA (1) CA2644156A1 (no)
CR (1) CR10234A (no)
EC (1) ECSP088719A (no)
IL (1) IL193636A0 (no)
MX (1) MX2008011458A (no)
NO (1) NO20083716L (no)
PE (1) PE20080138A1 (no)
RU (1) RU2008134369A (no)
SV (1) SV2009003017A (no)
TW (1) TW200812622A (no)
WO (1) WO2007103348A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005292647A1 (en) * 2004-08-10 2006-04-13 Wyeth CCI-779 derivatives and methods of making same
TW200824713A (en) 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
IT1394309B1 (it) * 2009-05-22 2012-06-06 Poli Ind Chimica Spa Nuovo approccio chimico-enzimatico alla sintesi del pimecrolimus
PL2859001T3 (pl) * 2012-06-08 2016-08-31 Biotronik Ag 40-o-podstawiona pochodna estrowa rapamycyny i węglowodoru cyklicznego, kompozycje i metody
SG11201500566XA (en) 2012-08-16 2015-04-29 Pfizer Glycoconjugation processes and compositions
SG10201707632PA (en) 2013-03-15 2017-11-29 Biosensors Int Group Ltd Purification of rapamycin derivatives
CN104448295B (zh) * 2013-12-02 2018-01-23 北京键凯科技股份有限公司 聚乙二醇‑多爪寡肽键合的雷帕霉素衍生物
JP7123399B2 (ja) 2016-03-24 2022-08-23 ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド タクロリムスのコンジュゲート、その組成物およびその使用
CN108641075B (zh) * 2018-03-05 2019-12-06 江苏千之康生物医药科技有限公司 一类雷帕霉素及其衍生物的双短链聚乙二醇前药及其应用
CN110314236A (zh) * 2018-03-29 2019-10-11 天津键凯科技有限公司 聚乙二醇与雷帕霉素的结合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
KR100244164B1 (ko) 1997-07-15 2000-03-02 김용옥 수용성 고분자-타크로리무스 접합체 화합물 및 그의 제조 방법
US6331547B1 (en) * 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
DE60136200D1 (de) * 2000-09-19 2008-11-27 Wyeth Corp Wasserlösliche rapamycin-ester
ATE410431T1 (de) * 2004-04-14 2008-10-15 Wyeth Corp Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
SG152234A1 (en) * 2004-04-14 2009-05-29 Wyeth Corp Regiospecific synthesis of rapamycin 42-ester derivatives

Also Published As

Publication number Publication date
KR20080106225A (ko) 2008-12-04
BRPI0708562A2 (pt) 2011-06-07
IL193636A0 (en) 2009-05-04
US7605257B2 (en) 2009-10-20
RU2008134369A (ru) 2010-04-20
CA2644156A1 (en) 2007-09-13
JP2009529050A (ja) 2009-08-13
TW200812622A (en) 2008-03-16
AR059740A1 (es) 2008-04-23
EP1993610A2 (en) 2008-11-26
ECSP088719A (es) 2008-10-31
US20070212371A1 (en) 2007-09-13
CR10234A (es) 2008-10-29
WO2007103348A2 (en) 2007-09-13
AU2007223963A1 (en) 2007-09-13
SV2009003017A (es) 2009-03-04
WO2007103348A3 (en) 2008-05-08
CN101394867A (zh) 2009-03-25
PE20080138A1 (es) 2008-03-05
MX2008011458A (es) 2008-09-24

Similar Documents

Publication Publication Date Title
NO20083716L (no) Prosess for tilberedning av vannloselige polyetylenglykol konjugater av immunosuppressive makrolider.
MY146387A (en) Thieno-pyridine derivatives as mek inhibitors
TW200711504A (en) Methods and apparatus for providing a roaming support system
GB2475200B (en) Updating and utilizing dynamic process simulation in an operating process environment
MX2010008919A (es) Metodos y composiciones para detectar mocroorganismos.
EP2479405B8 (en) Gas turbine equipment utilizing high humidity
HK1120100A1 (en) Coanda gas burner apparatus and methods
WO2008008857A3 (en) Thiolated macromolecules and methods of making and using thereof
EP1660653A4 (en) BIODEGRADABLE CONJUGATES OF POLYMERS AND LIGANDS AND USE IN THE ISOLATION OF CELL SUBPOPULATIONS, CRYOPRESERVATION, CULTURE AND TRANSPLANTATION OF CELLS
FR2881434B1 (fr) Dispositif de support de culture de cellules
EP2299774A4 (en) ACTIVE ANTENNA, BASE STATION, METHOD OF UPDATING AMPLITUDE AND PHASE AND SIGNAL PROCESSING METHOD
BRPI0718303A2 (pt) Aparelho da estação de base e método
WO2008066558A3 (en) Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines
EP2340427A4 (en) Calibration systems and methods for tracer gas leak detection
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
EP1930415A4 (en) SCREENING METHOD FOR A COMPOUND CAPABLE OF IMPROVING THE PRODUCTION OF REGULATORY T CELLS AND PROCESS FOR PRODUCING REGULATORY T CELLS USING AN IMMUNOSUPPRESSE MACROLIDE ANTIBIOTIC
WO2007106456A3 (en) Detection of molecular interactions using a reduced affinity enzyme complementation reporter system
WO2007076501A3 (en) Endometriosis cell targeting peptide and uses thereof
WO2012097223A3 (en) Oligosaccharide conjugates for targeting bacteria and uses related thereto
WO2008070477A3 (en) Polymeric short interfering rna conjugates
EP1795586A4 (en) PROCESS FOR MUSHROOM CULTIVATION
TW200721226A (en) Method of making barrier partitions and articles
EP4141100A4 (en) GAS SUPPLY DEVICE FOR BIOREACTOR
ATE478950T1 (de) Verfahren und zusammensetzungen zum nachweis von immunantworten
WO2008024498A3 (en) A system for obfuscating identity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application